Literature DB >> 1306731

Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer.

D Saranath1, R G Panchal, R Nair, A R Mehta, V D Sanghavi, M G Deo.   

Abstract

The presence of epidermal growth factor receptor (EGF-R) gene was determined in 84 patients with squamous cell carcinoma (SCC) of the oropharyngeal region--a highly prevalent, chewing-tobacco associated malignancy in India, using Southern hybridisation analysis of DNA extracted from primary tumor tissues. We observed a 3- to 8-fold amplification of EGF-R gene in 19/66 (29%) of the SCCs of the oral cavity, and about 30-fold EGF-R amplification in 2/18 (11%) hypopharyngeal cancers. Dot blot analysis of total RNA from several tumour tissues, revealed overexpression of the EGF-R gene in the examined patients, with the EGF-R gene amplified. 4 patients with single copy EGF-R gene, did not exhibit overexpression of the gene. Within our sample set, no correlation was evident between EGF-R gene amplification and clinico-pathological parameters of the malignancy. The amplification and overexpression of the EGF-R gene observed in the primary tumour tissues of 25% (21/84) of the human oropharyngeal cancers, indicate possible involvement of the gene in the pathogenesis of these cancers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306731     DOI: 10.1016/0964-1955(92)90043-z

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  14 in total

1.  Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.

Authors:  Stefan Hartmann; Norbert Neckel; Axel Seher; Grit Mutzbauer; Roman C Brands; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2015-08-23       Impact factor: 3.573

2.  Deubiquitylating enzyme, USP9X, regulates proliferation of cells of head and neck cancer lines.

Authors:  D M Nanayakkara; M N Nguyen; S A Wood
Journal:  Cell Prolif       Date:  2016-07-04       Impact factor: 6.831

3.  Modulation of P-gp expression by lapatinib.

Authors:  Gráinne Dunne; Laura Breen; Denis M Collins; Sandra Roche; Martin Clynes; Robert O'Connor
Journal:  Invest New Drugs       Date:  2010-07-06       Impact factor: 3.850

4.  Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India.

Authors:  Tanuja Teni; Sagar Pawar; Vikram Sanghvi; Dhananjaya Saranath
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

5.  Mass spectrometric characterization of a series of adenosylated peptides acting as bisubstrate analogs of protein kinases.

Authors:  B W Gibson; D Medzihradszky; W M Hines; S Auriola; G L Kenyon
Journal:  J Am Soc Mass Spectrom       Date:  1994-05       Impact factor: 3.109

6.  Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Authors:  Yuh Baba; Masato Fujii; Yutaka Tokumaru; Yasumasa Kato
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

7.  Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.

Authors:  Qingguo Li; Daorong Wang; Jing Li; Ping Chen
Journal:  BMC Cancer       Date:  2011-06-27       Impact factor: 4.430

8.  HER 2/neu protein expression in colorectal cancer.

Authors:  B Schuell; T Gruenberger; W Scheithauer; Ch Zielinski; F Wrba
Journal:  BMC Cancer       Date:  2006-05-08       Impact factor: 4.430

9.  Epidermal growth factor and transforming growth factor alpha characteristics of human oral carcinoma cell lines.

Authors:  S S Prime; S M Game; J B Matthews; A Stone; M J Donnelly; W A Yeudall; V Patel; R Sposto; A Silverthorne; C Scully
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.

Authors:  Yuh Baba; Masato Fujii; Toyonobu Maeda; Atsuko Suzuki; Satoshi Yuzawa; Yasumasa Kato
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.